iBio's GAAP loss for 9 months of fiscal year 2022 was $33.25 million, up 42.5% from $23.327 million in the prior year. Revenue increased 23.5% to $2.322 million from $1.88 million a year earlier.

iBio's GAAP loss for 6 months of fiscal year 2022 was $20.86 million, up 33.2% from $15.665 million in the prior year. Revenue declined 2.9 times to $0.379 million from $1.115 million a year earlier.

iBio's GAAP loss for 3M 2022 fiscal year was $8.94 million, up 18.7% from $7.534 million in the prior year. Revenue declined 48.5% to $211,000 from $410,000 a year earlier.

iBio bought the remaining 30% of its subsidiary iBio CDMO, which holds the exclusive rights to manufacture drugs using the FastPharming system in the United States. iBio also purchased from Eastern Capital Limited a manufacturing facility whose facilities it had previously leased. iBio paid $28 million in cash and issued warrants to purchase 1,000,000 of its...